Suchergebnisse - (Subject:"PARP inhibitor")

PubPharm (359)

1

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Harvey-Jones, E. | Raghunandan, M. | Robbez-Masson, L. | +36

2

DePARylation is critical for S phase progression and cell survival

enthalten in: eLife | 2024

von Nie, L. | Wang, C. | Huang, M. | +10

UpdateOf: bioRxiv. 2024 Feb 02;:. - PMID 37577639

3

Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer

enthalten in: Cancer medicine | 2024

von Uekusa, R. | Yokoi, A. | Watanabe, E. | +9

4

NRG-GY012 : Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

enthalten in: Cancer | 2024

von Rimel, B. | Enserro, D. | Bender, D. | +10

5

Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor

enthalten in: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | 2024

von Teng, Q. | Lei, Z. | Wang, J. | +9

6

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment

enthalten in: Cancer letters | 2024

von Madorsky Rowdo, F. | Xiao, G. | Khramtsova, G. | +23

UpdateOf: bioRxiv. 2023 Jun 22;:. - PMID 38076873

7

Natural pentacyclic triterpenoid from Pristimerin sensitizes p53-deficient tumor to PARP inhibitor by ubiquitination of Chk1

enthalten in: Pharmacological research | 2024

von Tao, L. | Xia, X. | Kong, S. | +3

8

High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response

enthalten in: Journal of molecular medicine (Berlin, Germany) | 2024

von Pan, J. | Wang, Y. | Huang, S. | +13

9

Clinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs*48 variant for platinum-based drug and PARP inhibitor

enthalten in: Japanese journal of clinical oncology | 2024

von Akahira, R. | Fukuda, K. | Shimazu, K. | +5

10

Targeting BRCA and PALB2 in Pancreatic Cancer

enthalten in: Current treatment options in oncology | 2024

von Anbil, S. | Reiss, K.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[36]